Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMulti-Immune HR: Bispecific Antibodies in High-Risk Newly Diagnosed Multiple Myeloma
NCT07029776Phase 2Not yet recruiting
- Sponsor
- University of Arkansas
- Start
- Mar 2027
- Primary completion
- Apr 2030
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of teclistamab, talquetamab in multiple myeloma (MM), sponsored by University of Arkansas. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
teclistamabtalquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07029776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07029776.